Christopher V. Chien

Christopher V. Chien

Auto-generated profile, based on publicly available information

Christopher V. Chien

Knight Cardiovascular Institute, Oregon Health Sciences University, Beaverton (C.V.C.).

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MZMichael R Zile
Michael R Zile
ADAkshay S Desai
Akshay S Desai
MCMaria Rosa Costanzo
Maria Rosa Costanzo
ADAnique Ducharme
Anique Ducharme
AMAlan Maisel
Alan Maisel
JLJoAnn Lindenfeld
JoAnn Lindenfeld
During the coronavirus disease 2019 (COVID-19) pandemic, important changes in heart failure (HF) event rates have been widely reported, but few data address potential causes for these changes; several possibilities were examined in the GUIDE-HF study. From 15 March 2018 to 20 December 2019, patients were randomized to haemodynamic-guided management (treatment) vs. control for 12 months, with a primary endpoint of all-cause mortality plus HF events. Pre-COVID-19, the primary endpoint rate was 0.553 vs. 0.682 events/patient-year in the treatment vs. control group [hazard ratio (HR) 0.81, P = 0.049]. Treatment difference was no longer evident during COVID-19 (HR 1.11, P = 0.526), with a 21% decrease in the control group (0.536 events/patient-year) and no change in the treatment group (0.597 events/patient-year). Data reflecting provider-, disease-, and patient-dependent factors that might change the primary endpoint rate during COVID-19 were examined. Subject contact frequency was similar in the treatment vs. control group before and during COVID-19. During COVID-19, the monthly rate of medication changes fell 19.2% in the treatment vs. 10.7% in the control group to levels not different between groups (P = 0.362). COVID-19 was infrequent and not different between groups. Pulmonary artery pressure area under the curve decreased −98 mmHg-days in the treatment group vs. −100 mmHg-days in the controls (P = 0.867). Patient compliance with the study protocol was maintained during COVID-19 in both groups. During COVID-19, the primary event rate decreased in the controls and remained low in the treatment group, resulting in an effacement of group differences that were present pre-COVID-19. These outcomes did not result from changes in provider- or disease-dependent factors; pulmonary artery pressure decreased despite fewer medication changes, suggesting that patient-dependent factors played an important role in these outcomes. Clinical Trials.gov: NCT03387813 Patient-dependent factors played an important role in the outcomes of GUIDE-HF.

1 March 2015 in The American Journal of Cardiology
Verified
Journal Article
Closed access
JGJill M. Gelow
Jill M. Gelow
JMJames O. Mudd
James O. Mudd
CCChristopher V. Chien
Christopher V. Chien
CLChristopher S Lee
Christopher S Lee

1 March 2020 in Heart & Lung
Verified
Journal Article
Closed access
QDQuin Denfeld
Quin Denfeld
JBJulie T. Bidwell
Julie T. Bidwell
JGJill M. Gelow
Jill M. Gelow
JMJames O. Mudd
James O. Mudd
CCChristopher V. Chien
Christopher V. Chien
CLChristopher S. Lee
Christopher S. Lee

1 December 2018 in The American Journal of Cardiology
Verified
Journal Article
Closed access
TETariq Enezate
Tariq Enezate
JOJad Omran
Jad Omran
PCPatricia P. Chang
Patricia P. Chang
MPMitul Patel
Mitul Patel
CCChristopher Chien
Christopher Chien
EAEric Adler
Eric Adler

2 February 2022 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
JHJared J. Herr
Jared J. Herr
MTMichael Tong
Michael Tong
BDBenjamin D'SOuza
Benjamin D'SOuza
FSFarooq Sheikh
Farooq Sheikh
ALAnuradha Lala
Anuradha Lala
ARAshwin Ravichandran
Ashwin Ravichandran

9 February 2022 in European Journal of Cardiovascular Nursing
Verified
Journal Article
Closed access
PDF file
KFKenneth Faulkner
Kenneth Faulkner
CJCorrine Y Jurgens
Corrine Y Jurgens
QDQuin Denfeld
Quin Denfeld
CCChristopher V Chien
Christopher V Chien
JTJessica Harman Thompson
Jessica Harman Thompson
CLChristopher S Lee
Christopher S Lee
Dyspnoea is a common symptom of heart failure (HF) that often prompts patients to seek treatment. Implantation of a left ventricular assist device (LVAD) has been associated with reduced dyspnoea but it is unclear if all patients experience similar improvements in dyspnoea over time following LVAD implantation. Our aim was to identify distinct trajectories of dyspnoea symptoms over time following LVAD implantation and predictors of dyspnoea trajectory. We hypothesized that at least two, distinct trajectories of dyspnoea would be observed following LVAD implantation. This was a secondary analysis of data from the Profiling Biobehavioral Responses to Mechanical Support in Advanced Heart Failure study. In the parent study, sociodemographic and clinical data were collected prior to LVAD implantation and at 1, 3, and 6 months following LVAD implantation from a sample (n = 101) of patients with advanced HF. Latent growth mixture modelling was performed to identify distinct trajectories of dyspnoea symptoms. Backwards stepwise logistic regression was used to identify predictors of dyspnoea trajectory. Two, distinct trajectories of dyspnoea symptoms were identified: sustained improvement and unsustained improvement. Participants who experienced sustained improvement (86.7% of sample) demonstrated large, significant improvement in dyspnoea from pre-implantation to 3 months post-implant followed by smaller, non-significant improvement from 3 to 6 months. Participants who experienced unsustained improvement (13.3% of sample) demonstrated initial improvement from pre-implantation to 3 months post-implantation followed by worsening of dyspnoea from 3 to 6 months. Greater depressive symptoms at baseline and living alone were significant predictors of unsustained improvement. Patients experience different patterns of dyspnoea over time following LVAD implantation. Clinicians should inquire about living arrangements and depressive symptoms at each visit to determine risk of unsustained improvement in dyspnoea.